The safety of treating newly diagnosed epilepsy

References

• Ngugi AK, Kariuki SM, Bottomley C, et al. Incidence of epilepsy: a systematic review and meta-analysis. Neurology. 2011;77(10):1005–1012.
   PubMed Web of Science ®Google Scholar
• Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology. 2017;88(3):296–303.
   PubMed Web of Science ®Google Scholar
• Kotsopoulos IA, van Merode T, Kessels FG, et al. Systematic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia. 2002;43(11):1402–1409.
   PubMed Web of Science ®Google Scholar
• Kwon CS, Liu M, Quan H, et al. The incidence of injuries in persons with and without epilepsy—A population‐based study. Epilepsia. 2010;51(11):2247–2253.
   PubMed Web of Science ®Google Scholar
• Beghi E, Morbidity CC. Accidents in patients with epilepsy: results of a European cohort study. Epilepsia. 2002;43(9):1076–1083.
   PubMed Web of Science ®Google Scholar
• Chen Z, Liew D, Kwan P. Excess mortality and hospitalized morbidity in newly treated epilepsy patients. Neurology. 2016;87(7):718–725.
   PubMed Web of Science ®Google Scholar
• Nevalainen O, Ansakorpi H, Simola M, et al. Epilepsy-related clinical characteristics and mortality. Neurology. 2014;83(21):1968.
   PubMed Web of Science ®Google Scholar
• Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475–482.
   PubMed Web of Science ®Google Scholar
• Leone MA, Giussani G, Nevitt SJ, et al. Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. Cochrane Database Syst Rev. 2016;(5).
   PubMed Web of Science ®Google Scholar
• Kobau R, DiIorio C. Epilepsy self-management: a comparison of self-efficacy and outcome expectancy for medication adherence and lifestyle behaviors among people with epilepsy. Epilepsy Behav. 2003;4(3):217–225.
   PubMed Web of Science ®Google Scholar
• McKee HR, Privitera MD. Stress as a seizure precipitant: identification, associated factors, and treatment options. Seizure. 2017;44:21–26.
   PubMed Web of Science ®Google Scholar
• Buratti L, Natanti A, Viticchi G, et al. Impact of sleep disorders on the risk of seizure recurrence in juvenile myoclonic epilepsy. Epilepsy Behav. 2018;80:21–24.
   PubMed Web of Science ®Google Scholar
• Tang V, Poon WS, Kwan P. Mindfulness-based therapy for drug-resistant epilepsyAn assessor-blinded randomized trial. Neurology. 2015;85(13):1100–1107.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314–319.
   PubMed Web of Science ®Google Scholar
• Chen Z, Brodie MJ, Liew D, et al. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: A 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279–286.
   PubMed Web of Science ®Google Scholar
• Nevitt SJ, Sudell M, Weston J, et al. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017;6:Cd011412.
   PubMed Web of Science ®Google Scholar
• Gil-Nagel A, Burd S, Toledo M, et al. A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy. Seizure. 2018;54:61–66.
   PubMed Web of Science ®Google Scholar
• Holtkamp M, Delanty N, Sales F, et al. Eslicarbazepine acetate as monotherapy in clinical practice: outcomes from Euro-Esli. Acta Neurol Scand. 2019;139(1):49–63.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Cagnetti C, Foschi N, et al. Lacosamide monotherapy for partial onset seizures. Seizure. 2015;27:71–74.
   PubMed Web of Science ®Google Scholar
• Perucca P, Carter J, Vahle V, et al. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology. 2009;72(14):1223–1229.
   PubMed Web of Science ®Google Scholar
• Baker GA, Jacoby A, Buck D, et al. Quality of life of people with epilepsy: a European study. Epilepsia. 1997;38(3):353–362.
   PubMed Web of Science ®Google Scholar
• Krucoff MO, Chan AY, Harward SC, et al. Rates and predictors of success and failure in repeat epilepsy surgery: a meta-analysis and systematic review. Epilepsia. 2017;58(12):2133–2142.
   PubMed Web of Science ®Google Scholar
• Morrell M. Brain stimulation for epilepsy: can scheduled or responsive neurostimulation stop seizures? Curr Opin Neurol. 2006;19(2):164–168.
   PubMed Web of Science ®Google Scholar
• Martin K, Jackson CF, Levy RG, et al. Ketogenic diet and other dietary treatments for epilepsy. Cochrane Database Syst Rev. 2016;2:Cd001903.
   PubMedGoogle Scholar
• Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet [London, England]. 2000;356(9237):1255–1259.
   PubMed Web of Science ®Google Scholar
• Perucca E, Kwan P. Overtreatment in epilepsy. CNS Drugs. 2005;19(11):897–908.
   PubMed Web of Science ®Google Scholar
• Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):792–802.
   PubMed Web of Science ®Google Scholar
• Perucca E, Meador KJ. Adverse effects of antiepileptic drugs. Acta Neurol Scand. 2005;112(s181):30–35.
   Google Scholar
• Greenwood RS. Adverse effects of antiepileptic drugs. Epilepsia. 2000;41(Suppl 2):S42–52.
   PubMedGoogle Scholar
• Berkovic SF. Aggravation of generalized epilepsies. Epilepsia. 1998;39(S3):S11–S4.
   PubMedGoogle Scholar
• Krauss G. Current understanding of delayed anticonvulsant hypersensitivity reactions. Epilepsy Curr. 2006;6(2):33–37.
   PubMedGoogle Scholar
• Stephens JR, Levy RH. Valproate hepatotoxicity syndrome: hypotheses of pathogenesis. Pharmaceutisch Weekblad Sci Ed. 1992;14(3a):118–121.
   PubMedGoogle Scholar
• Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia. 2007;48(7):1223–1244.
   PubMed Web of Science ®Google Scholar
• Dussault PM, Lazzari AA. Epilepsy and osteoporosis risk. Curr Opin Endocrinol Diabetes Obes. 2017;24(6):395–401.
   PubMed Web of Science ®Google Scholar
• Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016;11. doi: 10.1002/14651858.CD010224.pub2.
   Web of Science ®Google Scholar
• Gedzelman E, Meador KJ. Antiepileptic drugs in women with epilepsy during pregnancy. Ther Adv Drug Saf. 2012;3(2):71–87.
   PubMedGoogle Scholar
• Kanemura H, Sano F, Y-I M, et al. Valproate sodium enhances body weight gain in patients with childhood epilepsy: a pathogenic mechanisms and open-label clinical trial of behavior therapy. Seizure. 2012;21(7):496–500.
   PubMed Web of Science ®Google Scholar
• Thompson PJ, Baxendale SA, Duncan JS, et al. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry. 2000;69(5):636–641.
   PubMed Web of Science ®Google Scholar
• Newman WD, Tocher K, Acheson JF. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye [London, England]. 2002;16(5):567–571.
   PubMed Web of Science ®Google Scholar
• Lawden MC, Eke T, Degg C, et al. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry. 1999;67(6):716–722.
   PubMed Web of Science ®Google Scholar
• Perucca P, Jacoby A, Marson AG, et al. Adverse antiepileptic drug effects in new-onset seizures: a case-control study. Neurology. 2011;76(3):273–279.
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia. 2001;42(10):1255–1260.
   PubMed Web of Science ®Google Scholar
• Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2006;61(3):246–255.
   PubMed Web of Science ®Google Scholar
• Johannessen SI, Landmark CJ. Antiepileptic drug interactions - principles and clinical implications. Curr Neuropharmacol. 2010;8(3):254–267.
   PubMed Web of Science ®Google Scholar
• Sander JW, Perucca E. Epilepsy and comorbidity: infections and antimicrobials usage in relation to epilepsy management. Acta Neurol Scand Suppl. 2003;180:16–22.
   PubMedGoogle Scholar
• Besag FM, Berry DJ, Pool F, et al. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia. 1998;39(2):183–187.
   PubMed Web of Science ®Google Scholar
• Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia. 2000;41(12):1597–1607.
   PubMed Web of Science ®Google Scholar
• Fleming J, Chetty M. Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005;28(2):96–101.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Zaccara G, Giovannelli F, et al. Antiepileptic monotherapy in newly diagnosed focal epilepsy.A network meta-analysis. Acta Neurol Scand. 2019;139(1):33–41.
   PubMed Web of Science ®Google Scholar
• Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med. 1985;313([3]):145–151.
   PubMed Web of Science ®Google Scholar
• Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults the department of veterans affairs epilepsy cooperative study no. 264 group. New Engl J Med. 1992;327(11):765–771.
   PubMed Web of Science ®Google Scholar
• Bootsma HP, Ricker L, Hekster YA, et al. The impact of side effects on long-term retention in three new antiepileptic drugs. Seizure. 2009;18(5):327–331.
   PubMed Web of Science ®Google Scholar
• Javed A, Cohen B, Detyniecki K, et al. Rates and predictors of patient-reported cognitive side effects of antiepileptic drugs: an extended follow-up. Seizure. 2015;29:34–40.
   PubMed Web of Science ®Google Scholar
• Fisher RS, Vickrey BG, Gibson P, et al. The impact of epilepsy from the patient‘s perspective II: views about therapy and health care. Epilepsy Res. 2000;41(1):53–61.
   PubMed Web of Science ®Google Scholar
• Gilliam F. Optimizing health outcomes in active epilepsy. Neurology. 2002;58(8 Suppl 5):S9–20.
   PubMed Web of Science ®Google Scholar
• Luoni C, Bisulli F, Canevini MP, et al. Determinants of health-related quality of life in pharmacoresistant epilepsy: results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments. Epilepsia. 2011;52(12):2181–2191.
   PubMed Web of Science ®Google Scholar
• Eddy CM, Rickards HE, Cavanna AE. The cognitive impact of antiepileptic drugs. Ther Adv Neurol Disord. 2011;4(6):385–407.
   PubMedGoogle Scholar
• Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet. 2005;365(9476):2007–2013.
   PubMed Web of Science ®Google Scholar
• Jacoby A, Gamble C, Doughty J, et al. Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures. Neurology. 2007;68(15):1188–1196.
   PubMed Web of Science ®Google Scholar
• Bao EL, Chao LY, Ni P, et al. Antiepileptic drug treatment after an unprovoked first seizure: A decision analysis. Neurology. 2018;91(15):e1429–e39.
   PubMed Web of Science ®Google Scholar
• Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia. 2007;48(7):1360–1365.
   PubMed Web of Science ®Google Scholar
• Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure. 2006;15(3):156–164.
   PubMed Web of Science ®Google Scholar
• Blackburn SCF, Oliart AD, Lag R, et al. Antiepileptics and blood dyscrasias: a cohort study. Pharmacother J Human Pharmacol Drug Ther. 1998;18(6):1277–1283.
   Google Scholar
• Pack AM. The association between antiepileptic drugs and bone disease. Epilepsy Curr. 2003;3(3):91–95.
   PubMedGoogle Scholar
• Pack AM, Morrell MJ. Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications. CNS Drugs. 2001;15(8):633–642.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E. Weight issues for people with epilepsy—A review. Epilepsia. 2007;48(s9):42–45.
   PubMedGoogle Scholar
• Mula M, Sander JW. Negative effects of antiepileptic drugs on mood in patients with Epilepsy. Drug Saf. 2007;30(7):555–567.
   PubMed Web of Science ®Google Scholar
• Ferrer P, Ballarín E, Sabaté M, et al. Antiepileptic drugs and suicide: a systematic review of adverse effects. Neuroepidemiology. 2014;42(2):107–120.
   PubMed Web of Science ®Google Scholar
• Canevini MP, De Sarro G, Galimberti CA, et al. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia. 2010;51(5):797–804.
   PubMed Web of Science ®Google Scholar
• Panelli RJ, Kilpatrick C, Moore SM, et al. The liverpool adverse events profile: relation to AED use and mood. Epilepsia. 2007;48(3):456–463.
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Kwan P. Epilepsy in elderly people. BMJ. 2005;331(7528):1317–1322.
   PubMed Web of Science ®Google Scholar
• Loring DW, Marino S, Meador KJ. Neuropsychological and behavioral effects of antiepilepsy drugs. Neuropsychol Rev. 2007;17(4):413–425.
   PubMed Web of Science ®Google Scholar
• Baker GA, Jacoby A, Buck D, et al. The quality of life of older people with epilepsy: findings from a UK community study. Seizure. 2001;10(2):92–99.
   PubMed Web of Science ®Google Scholar
• Zeber JE, Copeland LA, Pugh MJ. Variation in antiepileptic drug adherence among older patients with new-onset epilepsy. Ann Pharmacother. 2010;44(12):1896–1904.
   PubMed Web of Science ®Google Scholar
• Vu LC, Piccenna L, Kwan P, et al. New-onset epilepsy in the elderly. Br J Clin Pharmacol. 2018;84(10):2208–2217.
   PubMed Web of Science ®Google Scholar
• Bruun E, Virta LJ, Kalviainen R, et al. Co-morbidity and clinically significant interactions between antiepileptic drugs and other drugs in elderly patients with newly diagnosed epilepsy. Epilepsy Behav. 2017;73:71–76.
   PubMed Web of Science ®Google Scholar
• Gilliam FG, Fessler AJ, Baker G, et al. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology. 2004;62(1):23–27.
   PubMed Web of Science ®Google Scholar
• Ferrendelli JA. Concerns with antiepileptic drug initiation: safety, tolerability, and efficacy. Epilepsia. 2001;42(Suppl 4):28–30.
   PubMedGoogle Scholar
• Bradley PM, Lindsay B, Fleeman N. Care delivery and self management strategies for adults with epilepsy. Cochrane Database Syst Rev. 2016;2. doi: 10.1002/14651858.CD006244.pub3.
   PubMedGoogle Scholar
• Shorvon S. Antiepileptic drug therapy during pregnancy: the neurologist‘s perspective. J Med Genet. 2002;39([4]):248–250.
   PubMed Web of Science ®Google Scholar
• Patel SI, Pennell PB. Management of epilepsy during pregnancy: an update. Ther Adv Neurol Disord. 2016;9([2]):118–129.
   PubMed Web of Science ®Google Scholar
• Asadi-Pooya AA. High dose folic acid supplementation in women with epilepsy: are we sure it is safe?. Seizure. 2015;27:51–53.
   PubMed Web of Science ®Google Scholar
• Bruun E, Virta LJ, Kalviainen R, et al. Choice of the first anti-epileptic drug in elderly patients with newly diagnosed epilepsy: A finnish retrospective study. Seizure. 2015;31:27–32.
   PubMed Web of Science ®Google Scholar
• Meier C, Kraenzlin ME. Antiepileptics and bone health. Ther Adv Musculoskelet Dis. 2011;3([5]):235–243.
   PubMedGoogle Scholar
• Arora E, Singh H, Gupta YK. Impact of antiepileptic drugs on bone health: need for monitoring, treatment, and prevention strategies. J Family Med Prim Care. 2016;5(2):248–253.
   PubMedGoogle Scholar
• Powell G, Saunders M, Rigby A, et al. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. Cochrane Database Syst Rev. 2016;12:Cd007124.
   PubMed Web of Science ®Google Scholar
• Nag D, Garg RK, Agarwal A. A comparative evaluation of pharmacokinetics of conventional and slow-release carbamazepine formulation in newly treated patients of epilepsy: a random evaluation. J Assoc Physicians India. 1998;46([2]):185–188.
   PubMedGoogle Scholar
• Perucca E. Extended-release formulations of antiepileptic drugs: rationale and comparative value. Epilepsy Curr. 2009;9(6):153–157.
   PubMed Web of Science ®Google Scholar
• Arroyo S. de la Morena A. Life-threatening adverse events of antiepileptic drugs. Epilepsy Res. 2001;47(1–2):155–174.
   PubMed Web of Science ®Google Scholar
• Asconapé JJ, Penry JK, Dreifuss FE, et al. Valproate-associated pancreatitis. Epilepsia. 1993;34(1):177–183.
   PubMed Web of Science ®Google Scholar
• Hart RG, Easton JD. Carbamazepine and hematological monitoring. Ann Neurol. 1982;11(3):309–312.
   PubMed Web of Science ®Google Scholar
• EpiPMConsortium. A roadmap for precision medicine in the epilepsies. Lancet Neurol. 2015;14(12):1219–1228.
   PubMed Web of Science ®Google Scholar
• Man CB, Kwan P, Baum L, et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007;48(5):1015–1018.
   PubMed Web of Science ®Google Scholar
• Cheung YK, Cheng SH, Chan EJ, et al. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia. 2013;54(7):1307–1314.
   PubMed Web of Science ®Google Scholar
• Chen Z, Liew D, Kwan P. Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions. Neurology. 2014;83(22):2077–2084.
   PubMed Web of Science ®Google Scholar
• Chen Z, Liew D, Kwan P. Real-world efficiency of pharmacogenetic screening for carbamazepine-induced severe cutaneous adverse reactions. PLoS One. 2014;9(5):e96990.
   PubMed Web of Science ®Google Scholar
• Chen Z, Liew D, Kwan P. Real-world cost-effectiveness of pharmacogenetic screening for epilepsy treatment. Neurology. 2016;86(12):1086–1094.
   PubMed Web of Science ®Google Scholar
• Locharernkul C, Loplumlert J, Limotai C, et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia. 2008;49(12):2087–2091.
   PubMed Web of Science ®Google Scholar
• Leckband SG, Kelsoe JR, Dunnenberger HM, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther. 2013;94(3):324–328.
   PubMed Web of Science ®Google Scholar
• McCormack M, Alfirevic A, Bourgeois S, et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011;364(12):1134–1143.
   PubMed Web of Science ®Google Scholar
• Ozeki T, Mushiroda T, Yowang A, et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet. 2011;20([5]):1034–1041.
   PubMed Web of Science ®Google Scholar
• Yip VL, Marson AG, Jorgensen AL, et al. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther. 2012;92(6):757–765.
   PubMed Web of Science ®Google Scholar
• Shi YW, Min FL, Zhou D, et al. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. Neurology. 2017;88(23):2183–2191.
   PubMed Web of Science ®Google Scholar
• McCormack M, Gui H, Ingason A, et al. Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology. 2018;90(4):e332–e41.
   PubMed Web of Science ®Google Scholar
• Stewart JD, Horvath R, Baruffini E, et al. Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology [Baltimore, Md]. 2010;52([5]):1791–1796.
   PubMed Web of Science ®Google Scholar
• Saneto RP, Lee IC, Koenig MK, et al. POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders. Seizure. 2010;19(3):140–146.
   PubMed Web of Science ®Google Scholar
• Milligan CJ, Li M, Gazina EV, et al. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine. Ann Neurol. 2014;75(4):581–590.
   PubMed Web of Science ®Google Scholar
• Mikati MA, Jiang Y-H, Carboni M, et al. Quinidine in the treatment of KCNT1-positive epilepsies. Ann Neurol. 2015;78(6):995–999.
   PubMed Web of Science ®Google Scholar
• Mullen SA, Carney PW, Roten A, et al. Precision therapy for epilepsy due to KCNT1 mutations: A randomized trial of oral quinidine. Neurology. 2018;90(1):e67–e72.
   PubMed Web of Science ®Google Scholar
• Sivapalarajah S, Krishnakumar M, Bickerstaffe H, et al. The prescribable drugs with efficacy in experimental epilepsies [PDE3] database for drug repurposing research in epilepsy. Epilepsia. 2018;59(2):492–501.
   PubMed Web of Science ®Google Scholar
• Toledano M, Britton JW, McKeon A, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology. 2014;82(18):1578–1586.
   PubMed Web of Science ®Google Scholar
• Quek AM, Britton JW, McKeon A, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012;69(5):582–593.
   PubMedGoogle Scholar
• Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia. 2017;58(4):512–521.
   PubMed Web of Science ®Google Scholar
• Guo J, Guo J, Li J, et al. Statin treatment reduces the risk of poststroke seizures. Neurology. 2015;85(8):701–707.
   PubMed Web of Science ®Google Scholar
• Mirza N, Sills GJ, Pirmohamed M, et al. Identifying new antiepileptic drugs through genomics-based drug repurposing. Hum Mol Genet. 2017;26(3):527–537.
   PubMed Web of Science ®Google Scholar
• Barsky AJ, Saintfort R, Rogers MP, et al. Nonspecific medication side effects and the nocebo phenomenon. JAMA. 2002;287(5):622–627.
   PubMed Web of Science ®Google Scholar
• AVd W, Merlo D, Kalincik T, et al. The impact of location, time and practice effects on computerised cognitive testing using msreactor in people with multiple sclerosis. J Neurol Neurosurg. 2017;88(5):e1–e.
   Web of Science ®Google Scholar
• Montalban X, Mulero P, Midaglia L, et al. FLOODLIGHT: remote self-monitoring is accepted by patients and provides meaningful, continuous sensor-based outcomes consistent with and augmenting conventional in-clinic measures [P4.382]. Neurology. 2018;90(15 Supplement):P4.382.
   Google Scholar
• Soraya GV, Chan J, Nguyen TC, et al. An interdigitated electrode biosensor platform for rapid HLA-B*15:02 genotyping for prevention of drug hypersensitivity. Biosens Bioelectron. 2018;111:174–183.
   PubMed Web of Science ®Google Scholar